Insmed Incorporated (NASDAQ:INSM) Receives Consensus Rating of “Buy” from Analysts

Insmed Incorporated (NASDAQ:INSM) has been given a consensus rating of “Buy” by the sixteen analysts that are currently covering the stock, Marketbeat reports. Sixteen equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $83.67.

A number of equities analysts have recently issued reports on INSM shares. JPMorgan Chase & Co. upped their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Bank of America upped their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th.

Insmed Stock Performance

Shares of INSM stock opened at $81.44 on Friday. The business’s fifty day simple moving average is $72.69 and its 200-day simple moving average is $73.04. The company has a market cap of $14.57 billion, a PE ratio of -14.67 and a beta of 1.11. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a 12-month low of $21.92 and a 12-month high of $81.96.

Insiders Place Their Bets

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 214,630 shares of company stock valued at $15,913,869. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Insmed

Hedge funds have recently modified their holdings of the company. Jennison Associates LLC boosted its stake in shares of Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after acquiring an additional 4,560 shares in the last quarter. Capital CS Group LLC purchased a new stake in shares of Insmed during the 4th quarter worth about $586,000. Orion Portfolio Solutions LLC lifted its stake in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC lifted its stake in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after buying an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP lifted its stake in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.